The adipose tissue-derived stromal vascular fraction (SVF) is an ideal source of stem and stromal cells. The aim of this study was to examine whether and how xenogenic transplantation of human breast SVF restores erectile function in diabetic mice. Human SVF was isolated from five patients (age, 20-45 yr) undergoing reduction mammoplasty. Eight-week-old C57BL/6J mice were used, and diabetes was induced by intraperitoneal injection of streptozotocin. At 8 wk after induction of diabetes, the animals were randomly distributed into controls and diabetic mice treated with a single intracavernous injection of PBS, human SVF at different concentrations, or human SVF lysate. Two weeks later, erectile function was measured by cavernous nerve stimulation, and the penis was then harvested for biochemical examinations. Erectile function was significantly improved in diabetic mice treated with human SVF (2 3 10 5
INTRODUCTION
Penile erection is a complex neurovascular phenomenon that is mediated by coordinated functions of cavernous endothelial and smooth muscle cells as well as neuronal cells [1] . Erectile dysfunction (ED) is more common and occurs earlier in men with diabetes mellitus than in the general population [2] . Moreover, men with diabetic ED respond more poorly than the general ED population to the currently available oral phosphodiesterase-5 (PDE5) inhibitors [3] . The reduced efficacy of PDE5 inhibitors in men with diabetes may be attributable to insufficient nitric oxide (NO) bioavailability from severe endothelial dysfunction and neuropathy [4, 5] . Therefore, a new therapeutic strategy that regenerates cavernous endothelial cells and neuronal cells is required to restore endogenous NO bioactivity and physiologic penile erection in men with diabetic ED.
Recently, stem cells isolated from various organs, such as bone marrow, adipose tissue, and skeletal muscle, have been used in attempts to treat ED at a preclinical level [6, 7] . Adipose tissue has emerged as a viable source for stem cells, and adipose tissue-derived stem cells (ADSCs) have characteristics similar to those of bone marrow-derived mesenchymal stem cells (MSCs) in terms of self-renewal and multipotency [7, 8] . Intracavernous administration of cultured ADSCs has been shown to restore erectile function through preservation of cavernous endothelial and neuronal cell content in rat models of ED [9] [10] [11] . However, the procedures related to isolating and culturing the ADSCs have some limitations; these include the high cost of facilities and personnel, the potential risk of contamination with foreign serum and undefined proteins, and changes in functional characteristics resulting from repeated culturing procedures [12, 13] .
The adipose tissue-derived stromal vascular fraction (SVF) is an ideal source of stromal and stem cells that can be harvested without a culturing step [14, 15] . A recent study reported that autologous transplantation of uncultured SVF into the penis restores erectile function in mice with cavernous nerve injury by promoting neural regeneration and through an antifibrotic mechanism [16] . From a clinical standpoint, however, procuring adipose tissue from patients requires invasive procedures, such as liposuction or excision of adipose tissue, which may limit the clinical application of autologous SVF therapy, especially in patients with a non-life-threatening disease, such as ED. According to data from the American Society for Plastic Surgeons, about 80 000 breast reduction mammoplasties were performed in 2009 [17] . Breast tissue may serve as a major allogenic source of unused human adipose tissue, which avoids invasive liposuction procedures.
In the present study, therefore, as a prelude to testing the feasibility of allogenic transplantation of human SVF to treat ED, we investigated the effectiveness of xenogenic transplan-tation of freshly isolated human SVF in restoring erectile function in a mouse model of diabetic ED. We also directly compared the efficacy of xenogenic human SVF and syngeneic mouse SVF on the recovery of erectile function in diabetic mice.
MATERIALS AND METHODS
A Supplemental Methods section is available online in the Supplemental Data (Supplemental Data are available at www.biolreprod.org).
Isolation of SVF and Preparation of SVF Lysate
We obtained human breast tissue from five patients (age, 20-45 yr) undergoing reduction mammoplasty. All tissue donors provided informed consent, and the procedures were approved by the internal review board of Inha University School of Medicine. None of the patients reported chronic illness or systemic cardiovascular diseases. We also isolated SVF from epididymal adipose tissues of 10-wk-old C57BL/6J mice. Detailed methods for the isolation of SVF and SVF lysate are described in the Supplemental Methods.
Animals and Treatment
Animal experiments were approved by the Inha University Animal Care and Use Subcommittee. Diabetes was induced in 8-wk-old C57BL/6J mice by intraperitoneal injections of streptozotocin (50 mg/kg) for 5 days consecutively as previously described [5] . At 8 wk after the induction of diabetes, the animals were randomly distributed into seven groups: controls and diabetic mice treated with a single intracavernous injection of PBS, human SVF (5 3 10 4 , 2 3 10 5 , 5 3 10 5 , or 1 3 10 6 cells/20 ll, respectively), or human SVF lysate. Detail methods are described in the Supplemental Methods. We compared the efficacy of xenogenic and syngeneic SVF transplantation on the recovery of erectile function in the diabetic mice after a single intracavernous injection of human or mouse SVF (2 3 10 5 cells/20 ll, respectively).
Nerve-Mediated Erection Studies
The mice from each diabetic group and their age-matched controls were anesthetized with ketamine (100 mg/kg) and xylazine (5 mg/kg) intramuscularly. Bipolar platinum wire electrodes were placed around the cavernous nerve. Stimulation parameters were 1-5 V at a frequency of 12 Hz, a pulse width of 1 msec, and a duration of 1 min. During tumescence, the maximal intracavernous pressure (ICP) was recorded. The total ICP was determined by the area under the curve from the beginning of cavernous nerve stimulation to a point 20 sec after stimulus termination. Systemic blood pressure was measured with a noninvasive tail-cuff system (Visitech Systems). The ratios of maximal ICP and total ICP to mean systolic blood pressure (MSBP) were calculated to normalize for variations in systemic blood pressure.
Immunohistochemistry
The penis tissue was fixed in 4% paraformaldehyde for 24 h at 48C, and frozen tissue sections (section thickness, 8 lm) were incubated with antibodies to platelet/endothelial cell adhesion molecule-1 (PECAM-1; an endothelial cell marker; 1:50; BD Biosciences), phosphorylated endothelial NO synthase (phospho-eNOS; Ser1177; 1:25; Cell Signaling Technology), fluorescein isothiocyanate (FITC)-conjugated antibody to smooth muscle a-actin (a smooth muscle cell marker; 1:200; Sigma-Aldrich), neurofilament (an axonal marker; 1:100; Sigma-Aldrich), neuronal NO synthase (nNOS; 1:100; Santa Cruz Biotechnology), and anti-human nuclei (1:50; Millipore) at 48C overnight. Control sections were incubated without the primary antibody at this step. After three washes with PBS, the sections were incubated with tetramethyl rhodamine isothiocyanate (Zymed Laboratories)-, FITC (Molecular Probes)-, or Alexa 488 (Invitrogen)-conjugated secondary antibodies for 2 h at room temperature. Signals were visualized, and digital images were obtained with a confocal microscope (FV1000; Olympus). Quantitative analysis of the endothelial cell, smooth muscle cell, and phospho-eNOS-immunopositive areas in the corpus cavernosum was done with an image-analyzer system (Image J 1.34; National Institutes of Health; http://rsbweb.nih.gov/ij/). 
Western Blot Analysis
Penile tissues that had been stored in liquid nitrogen were homogenized with a small volume of liquid nitrogen. This experimental step was repeated several times until the tissues changed into the complete powder. Radioimmunoprecipitation assay (RIPA) buffer (200 ll; a protease inhibitor cocktail; Sigma-Aldrich) was added to the homogenates, which were then transferred to 1.5-ml microcentrifuge tubes. After incubation on ice for 20 min, the homogenates were centrifuged at 13 000 3 g for 10 min at 48C, and the concentrations of each protein in the supernatants were measured using a Universal Microplate Reader ELx800G (BioTek Instruments). Equal amounts of protein (100 lg/lane) were electrophoresed on sodium dodecylsulfatepolyacrylamide gels (8%), transferred to nitrocellulose membranes, and probed with antibodies to eNOS (1:300; Transduction Laboratories), phospho-eNOS (Ser1177; 1:300; Cell Signaling Technology), nNOS (1:200; Santa Cruz Biotechnology), and b-actin (1:5000; Abcam). The results were representative of n ¼ 4 per group.
Estimation of Serum TNF-a and IL-6 Levels
Blood was extracted from control or human SVF-treated diabetic mice. Serum tumor necrosis factor (TNF)-a and interleukin (IL)-6 levels were estimated by using mouse TNF-a and IL-6 kits (R&D Systems). The kits were solid-phase sandwich enzyme-linked immunosorbent assays that used a microtiter plate reader at 450 nm. The concentrations of TNF-a and IL-6 were calculated from plotted standard curves.
Angiogenic Antibody Array
To detect the levels of angiogenic growth factors in human SVF lysate and conditioned medium, an antibody-based angiogenic array system (RayBio Human Angiogenesis Antibody Array 2; RayBiotech) was used. The detailed method is described in the Supplemental Methods.
Statistical Analysis
Results are expressed as the mean 6 SD. Statistical analysis was performed using one-way ANOVA followed by Student-Newman-Keuls post-hoc tests. Probability values of less than 5% were considered to be significant. Statistical analyses were performed using SigmaStat 3.11 software (Systat Software).
RESULTS

Metabolic and Physiologic Variables
Metabolic and physiologic variables in the seven groups of mice, including body weight, blood glucose concentrations, and systolic blood pressure, are summarized in Supplemental  Table S1 .
Presence of Human SVF in Diabetic Corpus Cavernosum Tissue
Immunofluorescent double-staining of cavernous tissue with 4 0 ,6-diamidino-2-phenylindole (DAPI) and anti-human nucleus antibody demonstrated that human SVF cells were present in the cavernous tissue of diabetic mice at 2 wk after treatment (Fig. 1) .
Human SVF Transfer Significantly Restores Erectile Function in Diabetic Mice
A representative intracavernous tracing after stimulation of the cavernous nerve (1-5 V, 12 Hz, 1 msec) for 1 min in XENOGENIC AD-SVF TRANSPLANTATION RECOVERS ED control mice or diabetic mice 2 wk after treatment is shown in Fig. 2A . The ratios of maximal ICP and total ICP to MSBP were significantly lower in the PBS-treated diabetic mice than in the control mice. A significant increase in erectile response to cavernous nerve stimulation was recorded in diabetic mice that received a single intracavernous injection of human SVF lysate or human SVF at concentrations of 2 3 10 5 , 5 3 10 5 , and 1 3 10 6 cells/20 ll, which reached up to 80%-85% of control values (Fig. 2, B and C) . However, no significant recovery of erectile function was noted at a lower concentration of human SVF (5 3 10 4 cells/20 ll).
Comparative Erectile Function Analysis of Human and Mouse SVF in Diabetic Mice
We further compared the efficacy of xenogenic transplantation of human SVF with the syngeneic transplantation of mouse SVF in diabetic mice at 2 wk after treatment. Because we recently observed in diabetic mice that the highest recovery of erectile function was noted at a dose of 2 3 10 5 cells of mouse SVF [18] , we administered the same dose of human and mouse SVF into the corpus cavernosum tissue. Local delivery of human and mouse SVF induced a similar increment of erection parameters in the diabetic mice (Fig. 3) .
Human SVF Transfer Increases Cavernous Endothelial and Smooth Muscle Content and Induces Phosphorylation of eNOS in Diabetic Mice
We observed significantly lower cavernous endothelial and smooth muscle cell content in the PBS-treated diabetic mice than in control mice. At 2 wk after treatment, human SVF (5 3 10 5 and 1 3 10 6 cells/20 ll) completely restored cavernous endothelial and smooth muscle content (Fig. 4) . Cavernous phospho-eNOS (Ser1177) expression was also significantly lower in the PBS-treated diabetic mice than in the control mice. Intracavernous injection of human SVF (5 3 10 5 and 1 3 10 6 cells/20 ll) significantly increased endogenous eNOS phosphorylation in the diabetic mice, but the phosphorylation did not reach the level found in the control group (Fig. 5) .
Human SVF Transfer Promotes Nerve Regeneration in Diabetic Mice
We observed significantly lower expression of neurofilament and nNOS in the dorsal nerve bundle of PBS-treated diabetic mice than in the control mice. Intracavernous administration of human SVF (5 3 10 5 and 1 3 10 6 cells/20 ll) completely restored penile axonal contents (neurofilament) and nNOS-containing fibers as well as nerve contents in diabetic mice as determined by both immunohistochemistry and Western blot analysis (Fig. 6) . 
DAS ET AL.
FIG. 4.
Human SVF transfer increases cavernous endothelial and smooth muscle content. A) Anti-PECAM-1 (red) and smooth muscle a-actin (SMA; green) staining of cavernous tissue from age-matched control and diabetic mice 2 wk after intracavernous injection of PBS (20 ll) or SVF (5 3 10 5 and 1 3 10 6 cells/20 ll). Bar ¼ 100 lm. B and C) Quantitative analysis of endothelial and smooth muscle area in cavernous tissue performed using an image analyzer. Bars depict the mean 6 SD from n ¼ 6 animals/group. *P , 0.01 vs. PBS-treated diabetic group. DM, diabetes mellitus; STZ, streptozotocin.
XENOGENIC AD-SVF TRANSPLANTATION RECOVERS ED
Human SVF Lysate Secretes Angiogenic Factors and Induces the Expression of Their Receptors
Because intracavernous injection of human SVF lysate restored erectile function in the diabetic mice to a level similar to that found in the human SVF-treated groups (5 3 10 5 and 1 3 10 6 cells/20 ll), we next examined the SVF lysate-mediated production of angiogenic cytokines and their receptors with the use of an angiogenic array system to determine the paracrine effect. The results showed that human SVF lysate induced higher levels of angiogenic factors and their receptors than found in the culture-medium (without-serum) control and in the human SVF-conditioned medium (Fig. 7) .
FIG. 5. Human SVF transfer induces cavernous eNOS phosphorylation.
A) Anti-PECAM-1 (red) and phospho-eNOS (Ser1177; green) staining of cavernous tissue from age-matched control and diabetic mice 2 wk after intracavernous injection of PBS (20 ll) or SVF (5 3 10 5 and 1 3 10 6 cells/20 ll). Bar ¼ 100 lm. B) Quantitative analysis of phospho-eNOS-positive area in the cavernous tissue performed using an image analyzer. Bars depict the mean 6 SD from n ¼ 6 animals/group. *P , 0.01 vs. PBS-treated diabetic group. C) Western blot analysis demonstrating the relative abundance of phosphoeNOS (P-eNOS; Ser1177) and eNOS in each group. Corpus cavernosum tissues were harvested after electrical stimulation of the cavernous nerve for 1 min. Results were similar from four-independent experiments. DM, diabetes mellitus; p-eNOS, phosphorylated eNOS; STZ, streptozotocin.
DAS ET AL.
Human SVF Does Not Affect the Level of Serum Inflammatory Cytokines in Diabetic Mice
To test whether xenogenic transplantation of human SVF into the mouse penis induces systemic inflammatory responses, we checked serum levels of the proinflammatory cytokines TNF-a and IL-6. The serum TNF-a and IL-6 concentrations were significantly increased in diabetic mice compared with those in the controls. Intracavernous administration of human SVF (2 3 10 5 , 5 3 10 5 , and 1 3 10 6 cells/20 ll) did not affect the level of serum inflammatory cytokines, which was similar to that found in PBS-treated diabetic mice (Fig. 8) .
DISCUSSION
We showed that xenogenic transplantation of human breast SVF into the corpus cavernosum of diabetic mice significantly restored cavernous endothelial and smooth muscle cell contents, restored penile nNOS and neurofilament contents, and induced phosphorylation of eNOS (Ser1177). These changes restored erectile function in the diabetic mice. Xenogenic transplantation of human SVF did not increase serum levels of the proinflammatory cytokines TNF-a and IL-6.
Similar to previous studies showing decreases in cavernous endothelial and smooth muscle cell contents after diabetes [5, [18] [19] [20] , the cavernous endothelial and smooth muscle cell area was significantly less in PBS-treated diabetic mice than in the control group. In the present study, however, intracavernous injection of human SVF completely restored cavernous endothelial and smooth muscle cell content in the diabetic mice. SVF is known to be an important source of angiogenic factors, such as vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1), and hepatocyte growth factor [21] [22] [23] .
We recently reported in a mouse model of diabetic ED that intracavernous injection of syngeneic mouse SVF increased cavernous VEGF expression. Furthermore, SVF-induced endothelial cell regeneration and restoration of erectile function were diminished in the presence of VEGF-trap, a soluble VEGF-neutralizing antibody [18] . In the present study, human SVF lysate enhanced the secretion of angiogenic factors and the expression of their receptors, and intracavernous injection of human SVF lysate induced an increment in erectile function in the diabetic mice similar to that in those treated with human SVF cells (5 3 10 5 and 1 3 10 6 cells/20 ll). These findings support the existence of a paracrine effect that may play a crucial role in the recovery of cavernous endothelial integrity and erectile function.
The nitrergic nerve generates survival signals to erectile tissue, and the amount of intact nNOS-positive neurons is critical for maintaining erectile function [24] . A previous study revealed a decrease in the number of nitrergic nNOScontaining nerve fibers in the penis of diabetic mice [25] . Our results also revealed a significant decrease in penile nNOS and neurofilament content in diabetic mice, which was completely restored by treatment with human SVF. It was reported previously that conditioned medium from adipose tissue-derived stromal cells inhibits neuronal apoptosis [26] . Bone marrow-derived MSCs are also known to induce neural regeneration in the penis of rats with type 1 diabetes mellitus by secreting neurotrophic factors, such as VEGF, nerve growth factor, and brain-derived neurotrophic factor [27] . Although we did not examine the penile expression of neurotrophic factors after administration of human SVF, the production of neurotrophic factors from SVF may play a major role in neural regeneration.
At 2 wk after intracavernous injection, we found a very small number of human SVF cells in the corpus cavernosum of diabetic mice. This finding is similar to those of previous investigators [10] , who showed disappearance of ADSCs after 4 wk of intracavernous injection. It was also reported that intracavernously injected ADSCs migrate to bone marrow due to the intrinsic property of stem cells [28] . These findings further support the importance of paracrine regulation.
In the present study, intracavernous injection of human SVF significantly induced phosphorylation of eNOS in the corpus cavernosum tissue of diabetic mice. Human SVF-mediated secretion of angiogenic factors and induction of their receptors as well as cavernous endothelial regeneration may account for the increased activity of eNOS in the diabetic mice. Thus, restoration of eNOS function and nNOS content may exert improved NO bioavailability.
We also examined whether xenogenic transplantation of human SVF into the corpus cavernosum of diabetic mice induces systemic inflammation. Inflammatory mediators have been known to induce islet beta-cell failure and insulin resistance [29] . Similar to these findings, serum levels of the proinflammatory cytokines TNF-a and IL-6 were significantly higher in diabetic mice than in the controls. Local delivery of human SVF did not increase the serum levels of proinflammatory cytokines in the diabetic mice in vivo, although SVF lysate does secrete TNF-a in vitro, which supports the feasibility of xenogenic or allogenic SVF therapy as a local treatment for ED. In the present study, we did not check the serum level of anti-inflammatory cytokines, such as IL10, which is known to decrease the secretion of proinflammatory cytokines and control inflammation [30] . The measurement of both proand anti-inflammatory cytokines may further support the suitability of xenogenic or allogenic SVF therapy.
To our knowledge, this is the first study to investigate the effectiveness and tolerability of xenogenic implantation of human SVF in restoring erectile function in a mouse model of diabetic ED, as a prelude to testing the feasibility and tolerability of allogenic human SVF therapy for the treatment of ED. Recently, autologous SVF therapy has been investigated in clinical trials in several fields, such as myocardial infarction, diabetes, and traumatic bone defect [31] . However, the application of autologous SVF therapy to human patients with ED is limited because the procedures used to harvest the adipose tissue, such as liposuction, are invasive. This is particularly problematic because the majority of patients with ED may require repeated injections of SVF for improved and durable clinical outcomes. Moreover, MSCs from diseased patients are known to be defective both structurally and functionally [32] , which favors allogenic rather than autologous MSC transplantation. In this regard, allogenic transplantation of SVF is viable option that obviates the inconveniences and morbidity associated with liposuction and improves effectiveness. However, safety issues should be completely resolved with strict criteria before the initiation of clinical trials.
The present study has limitations. First, the exact composition of the human SVF was not examined. Second, further studies are necessary to document the long-term efficacy of human SVF therapy either by single or repeated intracavernous injections.
Xenogenic transplantation of human breast SVF successfully improved erectile function in diabetic mice through enhanced penile angiogenesis and neural regeneration. Local delivery of human SVF did not induce systemic inflammation in the diabetic mice. Our preclinical findings should open a new avenue in the clinical application of allogenic SVF therapy for ED.
